JD Supra

Key Takeaways from FDA’s Draft Guidance on Use of AI in Drug and Biological Life Cycle

The US Food and Drug Administration (FDA) recently issued its draft guidance, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological ...

Navigating the Animal Rule in Drug Development with Modeling & Simulation, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how modeling and simulation can help navigate the Animal Rule in drug development. Attendees will gain insight into when the Animal Rule is appropriate to use for drug ...
Business Wire

Simulations Plus and the University of Connecticut Receive New FDA Grant to Expand Mechanistic Modeling Approaches for Long-Acting Injectables

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and ...
Morningstar

Simulations Plus Positioned to Capitalize on FDA’s Streamlined Nonclinical Safety Guidance with Advanced Mechanistic and Model-Informed Solutions

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today responded to ...
Nasdaq

FDA grants Simulations Plus to use PBPK to expand mechanistic modeling for LAI

Simulations Plus (SLP) announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration FDA to use physiologically based pharmacokinetic PBPK approaches in GastroPlus ...
The Daily Overview on MSN

Nvidia teams with biotech giants to supercharge AI drug discovery

Nvidia is turning its AI firepower toward the hardest problems in medicine, striking multibillion-dollar alliances with ...